Table 1.
Summary of the clinicopathological data of the 177 and 89 STS samples
| Factor | Diagnostic signature n = 177 | Prognostic signature n = 89 |
| Sex (male/female) | 88/89 | 50/39 |
| Age, median (range) years | 66 (11 – 94) | 69 (33 – 93) |
| Histological subtypes | ||
| Malignant fibrous histiocytoma (MFH) | 61¤ | 54 |
| Leiomyosarcoma | 40 | 27 |
| Synovial sarcoma | 32 | 0 |
| Liposarcoma | 16* | 0 |
| Malignant peripheral nerve sheath tumor | 8 | 0 |
| Myofibroblastic sarcoma | 5 | 5 |
| STS not otherwise specified | 4 | 2 |
| Extraskeletal osteosarcoma | 3 | 1 |
| Fibrosarcoma | 3 | 0 |
| Gastrointestinal stromal tumors | 3 | 0 |
| Epithelioid sarcoma | 1 | 0 |
| Malignant mesenchymoma | 1 | 0 |
| Grade | ||
| II | 6 | 1 |
| III | 32 | 12 |
| IV | 139 | 76 |
| Tumor size | ||
| Median (range) cm | 8 (1–40) | 9 (2–30) |
| < 5 cm | 41 | 19 |
| 5 – 10 cm | 74 | 38 |
| >10 cm | 62 | 32 |
| Tumor location | ||
| Extremity | 144 | 78 |
| Trunk wall | 19 | 7 |
| Retroperitoneum | 7 | 3 |
| Other | 7# | 1 |
| Tumor depth | ||
| Superficial | 37 | 22 |
| Deep | 118 | 63 |
| Unclassified | 22 | 4 |
| Necrosis | ||
| Absent | 48 | 23 |
| Present | 106 | 66 |
| Unclassified | 23 | 0 |
| Vascular invasion | ||
| Absent | 121 | 72 |
| Present | 31 | 17 |
| Unclassified | 25 | 0 |
| Treatment | ||
| Surgery alone | 107 | 58 |
| Postoperative radiotherapy | 51 | 22 |
| Postoperative chemotherapy | 3 | 2 |
| Postoperative radio- and chemotherapy | 10 | 7 |
| Preoperative radio- or chemotherapy | 6 | 0 |
| Surgery | ||
| Wide | 90 | 57 |
| Marginal | 66 | 28 |
| Intralesional | 15 | 4 |
| Unclassified | 6 | 0 |
¤Includes 47 storiform, 13 myxoid, and 1 giant-cell MFH
* Includes 4 myxoid/round cell liposarcomas, 6 dedifferentiated liposarcomas, and 6 pleomorphic liposarcomas
# Includes localizations in the abdomen, the mediastinum, and the head and neck